HDAC10 promotes lung cancer proliferation via AKT phosphorylation

Oncotarget

Volumn 7, Issue 37, 2016, Pages 59388-59401

  Yang, Yiwei ^a   Huang, Yitong ^a   Wang, Zhantong ^a   Wang, Hsin Tzu ^a   Duan, Baoyu ^a   Ye, Dan ^a   Wang, Chenxin ^a   Jing, Ruiqi ^a   Leng, Ye ^a   Xi, Jiajie ^a   Chen, Wen ^a   Wang, Guiying ^a   Jia, Wenwen ^a   Zhu, Songcheng ^a   Kang, Jiuhong ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

AKT; Cell cycle; Cellular localization; Histone deacetylase 10 (HDAC10); Lung cancer

Indexed keywords

HISTONE DEACETYLASE 10; LEUCINE; PROTEIN KINASE B; SERINE; HDAC10 PROTEIN, HUMAN; HISTONE DEACETYLASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG CANCER CELL LINE; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; ANIMAL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; RESPIRATORY MUCOSA; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RESPIRATORY MUCOSA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84991314188     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10673     Document Type: Article

References (36)

1. Chen YJ, Chen LX, Han MX, Zhang TS, Zhou ZR and Zhong DS. The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review. Medicine. 2015; 94:e1451
2. England CG, Ng CF, Berkel V and Frieboes HB. A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity. Current drug targets. 2015; 16:1057-1087
3. Sun Z, Wang Z, Liu X and Wang D. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anticancer drugs. 2015; 26:1-14
4. Fumarola C, Bonelli MA, Petronini PG and Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochemical pharmacology. 2014; 90:197-207
5. Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y, Deng A, Chen J, Wang G, Zhu S and Kang J. Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. The Journal of biological chemistry. 2013; 288:14510-14521
6. Pinton G, Manente AG, Murer B, De Marino E, Mutti L and Moro L. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. Journal of cellular and molecular medicine. 2013; 17:233-241
7. Li XH, Chen C, Tu Y, Sun HT, Zhao ML, Cheng SX, Qu Y and Zhang S. Sirt1 promotes axonogenesis by deacetylation of Akt and inactivation of GSK3. Molecular neurobiology. 2013; 48:490-499
8. Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E and Castronovo V. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. European journal of histochemistry: EJH. 2004; 48:273-290
9. Kawai H, Li H, Avraham S, Jiang S and Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. International journal of cancer Journal international du cancer. 2003; 107:353-358
10. Wang J, Elahi A, Ajidahun A, Clark W, Hernandez J, Achille A, Hao JH, Seto E and Shibata D. The interplay between histone deacetylases and c-Myc in the transcriptional suppression of HPP1 in colon cancer. Cancer biology & therapy. 2014; 15:1198-1207
11. Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, Bradner JE, Dalton WS, Sotomayor E, et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. The Journal of clinical investigation. 2013; 123:4612-4626
12. Vendetti FP and Rudin CM. Epigenetic therapy in nonsmall-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert opinion on biological therapy. 2013; 13:1273-1285
13. Petta V, Gkiozos I, Strimpakos A and Syrigos K. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Cancer chemotherapy and pharmacology. 2013; 72:935-952
14. Parra M and Verdin E. Regulatory signal transduction pathways for class IIa histone deacetylases. Current opinion in pharmacology. 2010; 10:454-460
15. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC and Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert review of anticancer therapy. 2010; 10:935-954
16. Tong JJ, Liu J, Bertos NR and Yang XJ. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic acids research. 2002; 30:1114-1123
17. Kao HY, Lee CH, Komarov A, Han CC and Evans RM. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. The Journal of biological chemistry. 2002; 277:187-193
18. Guardiola AR and Yao TP. Molecular cloning and characterization of a novel histone deacetylase HDAC10. The Journal of biological chemistry. 2002; 277:3350-3356
19. Kotian S, Liyanarachchi S, Zelent A and Parvin JD. Histone deacetylases 9 and 10 are required for homologous recombination. The Journal of biological chemistry. 2011; 286:7722-7726
20. Oehme I, Linke JP, Bock BC, Milde T, Lodrini M, Hartenstein B, Wiegand I, Eckert C, Roth W, Kool M, Kaden S, Grone HJ, Schulte JH, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:E2592-2601
21. Song C, Zhu S, Wu C and Kang J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. The Journal of biological chemistry. 2013; 288:28021-28033
22. Li Y, Peng L and Seto E. Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7-HMGA2-Cyclin A2 Pathway. Molecular and cellular biology. 2015; 35:3547-3565
23. Domingo G, Perez CA, Velez M, Cudris J, Raez LE and Santos ES. EGF receptor in lung cancer: a successful story of targeted therapy. Expert review of anticancer therapy. 2010; 10:1577-1587
24. Phuchareon J, McCormick F, Eisele DW and Tetsu O. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:E3855-3863
25. Risso G, Blaustein M, Pozzi B, Mammi P and Srebrow A. Akt/PKB: one kinase, many modifications. The Biochemical journal. 2015; 468:203-214
26. Cuffe S and Leighl NB. Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011; 6:S1805-1807
27. Soderholm JF, Bird SL, Kalab P, Sampathkumar Y, Hasegawa K, Uehara-Bingen M, Weis K and Heald R. Importazole, a small molecule inhibitor of the transport receptor importin-beta. ACS chemical biology. 2011; 6:700-708
28. Zhu L, Wu K, Ma S and Zhang S. HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer. Tumori. 2015; 101:257-262
29. Kumar A, Singh UK and Chaudhary A. Targeting autophagy to overcome drug resistance in cancer therapy. Future medicinal chemistry. 2015; 7:1535-1542
30. Oehme I, Lodrini M, Brady NR and Witt O. Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas. Autophagy. 2013; 9:2163-2165
31. Jones PL and Shi YB. N-CoR-HDAC corepressor complexes: roles in transcriptional regulation by nuclear hormone receptors. Current topics in microbiology and immunology. 2003; 274:237-268
32. Nicolas E, Yamada T, Cam HP, Fitzgerald PC, Kobayashi R and Grewal SI. Distinct roles of HDAC complexes in promoter silencing, antisense suppression and DNA damage protection. Nature structural & molecular biology. 2007; 14:372-380
33. Roguev A and Krogan NJ. SIN-fully silent: HDAC complexes in fission yeast. Nature structural & molecular biology. 2007; 14:358-359
34. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M and Gupta MP. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Science signaling. 2011; 4:ra46
35. Horio Y. Diabetes: insulin signal meets SIRT1 at AKT. Nature reviews Endocrinology. 2012; 8:131-132
36. Zhu S, Jing R, Yang Y, Huang Y, Wang X, Leng Y, Xi J, Wang G, Jia W and Kang J. A motif from Lys216 to Lys222 in human BUB3 protein is a nuclear localization signal and critical for BUB3 function in mitotic checkpoint. The Journal of biological chemistry. 2015; 290:11282-11292